Quality Systems Ties Up With CoverMyMeds to Enable ePA

Quality Systems, Inc. QSII, also known as NextGen Healthcare, recently announced that its electronic health record (EHR) ambulatory product NextGen Office has been integrated with CoverMyMeds. Notably, CoverMyMeds, the largest electronic prior authorization (ePA) solution of the United States, is owned by McKesson Corporation MCK.

It enables providers, pharmacists and their staff to fill out Prior Authorization (PA) requests electronically digressing from the manual methods of obtaining PAs through paper, faxes, and phone calls between providers, pharmacies and insurers.

The latest developmentwill help NextGen Office users get faster Prior Authorization (PA) and lessen the time spent by providers.Some of the benefits of the alliance include faster completion of PA requests, streamlined communications, ease of workflow and tracking the status of PAs.

For investors’ notice, PA in healthcare implies planning the necessaryhealth careservice, treatment plan, prescription drug or durable medical equipment by health insurers. However, traditional methods of PA are time-consuming.

Per an article in HealthPayer Intelligence, the largest tax payers of the United States like Aetna, Anthem, Cigna and Humana have committed to the use of electronic prior authorization to streamline approval procedures for providers and patients. This decreases turnaround time.

An article by P&S Market Research states that the global EHR market is projected to reach a worth of $30.4 billion by 2023.

The market is mainly driven by the increasing need for advanced healthcare information system, growing investments by healthcare IT players, rising demand for better healthcare facilities and increasing government initiatives.

Hence, Quality System’s latest move has been a well-timed one.

In the past year, shares of Quality Systems have rallied 45.4% compared with the industry’s 8.6% rise.

Quality Systems carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the Medical Info Systems industry are athenahealth ATHN and FULGENT GENETIC FLGT.

athenahealth has a long-term expected earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

FULGENT GENETIC has a projected earnings growth rate of 11.1% for the next year. The stock carries a Zacks Rank #2 (Buy).

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 – 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.